Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinopharm and Provectus Extend MOU Negotiations for Six Months

publication date: Nov 14, 2014
Sinopharm (China National Pharmaceutical Group) and Provectus Biopharma of the US have extended their MOU for another six months to May 16, 2015. During the first three months of the agreement (see story), the two companies were not able to come to terms on China rights for Provectus's lead drug candidate: PV-10, a cancer immunotherapy. According to reports, Sinopharm will study the recently published protocol for the melanoma Phase III trial of PV-10 to "understand the drug better." More details....

Stock Symbol: (NYSE: PVCT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital